To assess the safety, reactogenicity % immunogenicity of a 4th dose of GSK Biologicals’ pneumococcal vaccine or Prevenar™ in children (12-18 months) previously vaccinated in the primary study 105553 with either pneumococcal vaccine or Prevenar™
Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
Infections, Streptococcal
Phase 3
This is a booster study of 105553. Follow on studies 112640, 111345, 111346, and 111347 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.
October 2014